Zymeworks signs exclusive global license with Roche for ZW209, a DLL3 trispecific T cell engager
FROM THE WIRE · FINANCE.YAHOO.COM
Zymeworks Inc. Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones Zymeworks also eligible to receive tiered…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe deal brings a $55M upfront and up to $718M in milestones, a positive development for Zymeworks.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Zymeworks will receive $55M upfront and $40M upon initiation of the Phase 1b trial.
- 02Additional milestones of up to $718M and tiered royalties on global net sales are possible.
- 03The transaction is subject to expiration of the HSR waiting period.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Zymeworks Inc.28.44 USDMarket closedtoday +1.16%Positive Roche Holding AG59.61 USDMarket closedtoday +0.85%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets